Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16260821.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease. To perform such an evaluation. We randomly assigned 79 of 156 patients treated with donepezil to receive a reality orientation programme. Caregivers of the treatment group were trained to offer the programme at home 3 days a week, 30 min/day, for 25 consecutive weeks, and were invited to stimulate and involve patients in reality-based communication. The treatment group showed a slight improvement in Mini-Mental State Examination (MMSE) scores (mean change +0.2, s.e.=0.4) compared with a decline in the control group (mean change -1.1, s.e.=0.4; P=0.02). Similarly for the Alzheimer's Disease Assessment Scale--Cognition (treatment group mean change +0.4, s.e.=0.8; control group -2.5, s.e.=0.8; P=0.01). The intervention had an equal effect on cognition in those with mild (MMSE score > or = 20) and moderate (score <20) dementia. No significant effect was observed for behavioural and functional outcomes. Reality orientation enhances the effects of donepezil on cognition in Alzheimer's disease.
Medical subject headings
- Alzheimer Disease
- Cholinesterase Inhibitors
- Indans
- Piperidines
- Reality Therapy